MetaVia (MTVA) Competitors $1.00 -0.05 (-4.76%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock MTVA vs. AVTX, PYXS, ZURA, KALA, HURA, CGEN, SKYE, CGTX, TARA, and BMEAShould you be buying MetaVia stock or one of its competitors? The main competitors of MetaVia include Avalo Therapeutics (AVTX), Pyxis Oncology (PYXS), Zura Bio (ZURA), KALA BIO (KALA), TuHURA Biosciences (HURA), Compugen (CGEN), Skye Bioscience (SKYE), Cognition Therapeutics (CGTX), Protara Therapeutics (TARA), and Biomea Fusion (BMEA). These companies are all part of the "pharmaceutical products" industry. MetaVia vs. Its Competitors Avalo Therapeutics Pyxis Oncology Zura Bio KALA BIO TuHURA Biosciences Compugen Skye Bioscience Cognition Therapeutics Protara Therapeutics Biomea Fusion MetaVia (NASDAQ:MTVA) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations. Is MTVA or AVTX more profitable? Avalo Therapeutics' return on equity of -48.48% beat MetaVia's return on equity.Company Net Margins Return on Equity Return on Assets MetaViaN/A -212.00% -107.21% Avalo Therapeutics N/A -48.48%-35.94% Do analysts rate MTVA or AVTX? MetaVia presently has a consensus target price of $7.50, suggesting a potential upside of 650.00%. Avalo Therapeutics has a consensus target price of $31.67, suggesting a potential upside of 174.17%. Given MetaVia's higher possible upside, equities research analysts clearly believe MetaVia is more favorable than Avalo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Avalo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, MTVA or AVTX? MetaVia has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Does the media prefer MTVA or AVTX? In the previous week, Avalo Therapeutics had 3 more articles in the media than MetaVia. MarketBeat recorded 4 mentions for Avalo Therapeutics and 1 mentions for MetaVia. MetaVia's average media sentiment score of 0.95 beat Avalo Therapeutics' score of 0.82 indicating that MetaVia is being referred to more favorably in the media. Company Overall Sentiment MetaVia Positive Avalo Therapeutics Positive Do institutionals & insiders hold more shares of MTVA or AVTX? 1.4% of MetaVia shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 0.8% of MetaVia shares are held by insiders. Comparatively, 3.0% of Avalo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better earnings & valuation, MTVA or AVTX? MetaVia has higher earnings, but lower revenue than Avalo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetaViaN/AN/A-$27.59MN/AN/AAvalo Therapeutics$440K345.19-$35.13MN/AN/A SummaryAvalo Therapeutics beats MetaVia on 8 of the 11 factors compared between the two stocks. Get MetaVia News Delivered to You Automatically Sign up to receive the latest news and ratings for MTVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MTVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTVA vs. The Competition Export to ExcelMetricMetaViaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.41M$3.13B$5.75B$10.39BDividend YieldN/A2.39%5.77%4.64%P/E RatioN/A20.6375.7726.11Price / SalesN/A442.69544.74124.93Price / CashN/A44.6737.5461.24Price / Book1.099.6212.876.30Net Income-$27.59M-$52.73M$3.29B$271.03M7 Day Performance9.02%0.64%-0.26%-0.15%1 Month Performance53.87%6.31%3.84%6.41%1 Year PerformanceN/A18.97%68.35%28.81% MetaVia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTVAMetaVia2.1743 of 5 stars$1.00-4.8%$7.50+650.0%N/A$25.41MN/A0.008AVTXAvalo Therapeutics3.9336 of 5 stars$11.33+16.1%$31.67+179.5%+19.0%$128.36M$441K0.0040High Trading VolumePYXSPyxis Oncology2.3691 of 5 stars$2.21+7.8%$7.75+250.7%-39.7%$127.14M$2.82M-1.3860Gap UpHigh Trading VolumeZURAZura Bio3.7648 of 5 stars$1.90-3.1%$14.00+636.8%-42.8%$123.54MN/A-2.713Positive NewsKALAKALA BIO4.1562 of 5 stars$17.47-4.6%$27.50+57.4%+246.7%$122.64M$3.89M-2.5730Gap UpHigh Trading VolumeHURATuHURA Biosciences1.4609 of 5 stars$2.43-2.0%$12.67+421.3%N/A$121.62MN/A0.00N/ACGENCompugen1.5588 of 5 stars$1.36-1.4%$4.00+194.1%-20.5%$121.37M$27.86M-6.1870Positive NewsSKYESkye Bioscience1.8206 of 5 stars$3.91+1.3%$15.50+296.4%-10.7%$121.17MN/A-3.6911CGTXCognition Therapeutics2.8114 of 5 stars$1.47-8.7%$2.83+92.7%+176.5%$118.37MN/A-2.1920Positive NewsTARAProtara Therapeutics1.3977 of 5 stars$3.03-1.3%$19.60+546.9%+126.7%$116.90MN/A-1.8730BMEABiomea Fusion3.3377 of 5 stars$1.96-3.0%$14.80+655.1%-74.3%$116.64MN/A-0.6550 Related Companies and Tools Related Companies AVTX Alternatives PYXS Alternatives ZURA Alternatives KALA Alternatives HURA Alternatives CGEN Alternatives SKYE Alternatives CGTX Alternatives TARA Alternatives BMEA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MTVA) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MTVA Stock Alerts